妊娠女性COVID-19:妊娠丢失风险与患病率的系统综述与荟萃分析
该系统综述纳入120项研究共168444例SARS-CoV-2感染孕妇,其中18233例处于早或中孕期。分析未发现SARS-CoV-2感染与流产相关(OR 1.10,95%CI 0.81-1.48;I²=0.0%)。早孕期流产比例为9.9%(95%CI 6.2-14.0%),中孕期为1.2%(95%CI 0.3-2.4%)。
要点
- SARS-CoV-2感染与流产无显著关联(OR 1.10,95%CI 0.81-1.48)。
- 早孕期SARS-CoV-2感染孕妇流产比例为9.9%(95%CI 6.2-14.0%)。
- 中孕期 SARS-CoV-2 感染孕妇流产比例为1.2%(95%CI 0.3-2.4%)。
核心结论
- 未发现SARS-CoV-2感染在早孕期或中孕期增加流产风险的证据。
- 为提供更好的风险估计,需要设计良好的研究,纳入受孕时和早孕期有和无SARS-CoV-2感染的孕妇,并考虑SARS-CoV-2感染的临床表现和严重程度与妊娠丢失的关联,以及既往妊娠丢失等潜在混杂因素。
- 临床实践中,仍应建议孕妇采取预防措施避免SARS-CoV-2暴露风险并接种SARS-CoV-2疫苗。
研究设计与样本
- 系统综述基于前瞻性注册的方案,检索PregCov19联盟并补充额外电子检索,检索截至2023年3月10日,数据库包括PubMed、Google Scholar和LitCovid。
- 纳入报告早孕期和/或中孕期妊娠丢失信息的回顾性和前瞻性SARS-CoV-2感染孕妇研究。
- 共纳入120项研究,包含168444例SARS-CoV-2感染孕妇,其中18233例处于早孕期或中孕期。
- 至少三名研究者独立提取数据并评估研究质量,采用随机效应荟萃分析计算OR和风险差(RD)及95%CI,采用比例荟萃分析估计风险患病率,用I²评估异质性。
主要发现
- 未发现SARS-CoV-2感染与流产相关的证据(OR 1.10,95%CI 0.81-1.48;I²=0.0%;RD 0.0012,95%CI -0.0103至0.0127;I²=0%;9项研究,4439例女性)。
- 早孕期SARS-CoV-2感染女性流产比例为9.9%(95%CI 6.2-14.0%;I²=68%;46项研究,1797例女性)。
- 中孕期SARS-CoV-2感染女性流产比例为1.2%(95%CI 0.3-2.4%;I²=34%;33项研究;3159例女性)。
- SARS-CoV-2感染女性异位妊娠比例为1.4%(95%CI 0.02-4.2%;I²=66%;14项研究,950例女性)。
- 终止妊娠发生于0.6%的女性(95%CI 0.01-1.6%;I²=79%;39项研究;1166例女性)。
关键数值与推荐
- 主要结局为流产,定义为妊娠20周前的妊娠丢失,但报告至22或24周的丢失的研究也纳入。
- 也报告将妊娠丢失定义为发生于早孕期和/或中孕期但未指定孕周的研究,以及仅当研究将死产和/或胎儿丢失与流产分开报告时的中孕期流产。
- 数据按早孕期和中孕期分层。
- 次要结局为异位妊娠(任何宫外妊娠)和终止妊娠。
- 证据等级被认为是低至中等确定性,主要由于选择偏倚。
临床怎么用
- 临床实践中,仍应建议孕妇采取预防措施避免SARS-CoV-2暴露风险并接种SARS-CoV-2疫苗。
局限性
- 证据等级被认为是低至中等确定性,主要由于选择偏倚。
- 为提供更好的风险估计,需要设计良好的研究,纳入受孕时和早孕期有和无SARS-CoV-2感染的孕妇,并考虑SARS-CoV-2感染的临床表现和严重程度与妊娠丢失的关联,以及既往妊娠丢失等潜在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to experience preterm birth and their neonates are more likely to be stillborn or admitted to a neonatal unit. The World Health Organization declared in May 2023 an end to the coronavirus disease 2019 (COVID-19) pandemic as a global health emergency. However, pregnant women are still becoming infected with SARS-CoV-2 and there is limited information available regarding the effect of SARS-CoV-2 infection in early pregnancy on pregnancy outcomes. OBJECTIVE AND RATIONALE: We conducted this systematic review to determine the prevalence of early pregnancy loss in women with SARS-Cov-2 infection and compare the risk to pregnant women without SARS-CoV-2 infection. SEARCH METHODS: Our systematic review is based on a prospectively registered protocol. The search of PregCov19 consortium was supplemented with an extra electronic search specifically on pregnancy loss in pregnant women infected with SARS-CoV-2 up to 10 March 2023 in PubMed, Google Scholar, and LitCovid. We included retrospective and prospective studies of pregnant women with SARS-CoV-2 infection, provided that they contained information on pregnancy losses in the first and/or second trimester. Primary outcome was miscarriage defined as a pregnancy loss before 20 weeks of gestation, however, studies that reported loss up to 22 or 24 weeks were also included. Additionally, we report on studies that defined the pregnancy loss to occur at the first and/or second trimester of pregnancy without specifying gestational age, and for second trimester miscarriage only when the study presented stillbirths and/or foetal losses separately from miscarriages. Data were stratified into first and second trimester. Secondary outcomes were ectopic pregnancy (any extra-uterine pregnancy), and termination of pregnancy. At least three researchers independently extracted the data and assessed study quality. We calculated odds ratios (OR) and risk differences (RDs) with corresponding 95% CI and pooled the data using random effects meta-analysis. To estimate risk prevalence, we performed meta-analysis on proportions. Heterogeneity was assessed by I2. OUTCOMES: We included 120 studies comprising a total of 168 444 pregnant women with SARS-CoV-2 infection; of which 18 233 women were in their first or second trimester of pregnancy. Evidence level was considered to be of low to moderate certainty, mostly owing to selection bias. We did not find evidence of an association between SARS-CoV-2 infection and miscarriage (OR 1.10, 95% CI 0.81-1.48; I2 = 0.0%; RD 0.0012, 95% CI -0.0103 to 0.0127; I2 = 0%; 9 studies, 4439 women). Miscarriage occurred in 9.9% (95% CI 6.2-14.0%; I2 = 68%; 46 studies, 1797 women) of the women with SARS CoV-2 infection in their first trimester and in 1.2% (95% CI 0.3-2.4%; I2 = 34%; 33 studies; 3159 women) in the second trimester. The proportion of ectopic pregnancies in women with SARS-CoV-2 infection was 1.4% (95% CI 0.02-4.2%; I2 = 66%; 14 studies, 950 women). Termination of pregnancy occurred in 0.6% of the women (95% CI 0.01-1.6%; I2 = 79%; 39 studies; 1166 women). WIDER IMPLICATIONS: Our study found no indication that SARS-CoV-2 infection in the first or second trimester increases the risk of miscarriages. To provide better risk estimates, well-designed studies are needed that include pregnant women with and without SARS-CoV-2 infection at conception and early pregnancy and consider the association of clinical manifestation and severity of SARS-CoV-2 infection with pregnancy loss, as well as potential confounding factors such as previous pregnancy loss. For clinical practice, pregnant women should still be advised to take precautions to avoid risk of SARS-CoV-2 exposure and receive SARS-CoV-2 vaccination.
引用
- van Baar JAC, Kostova EB, Allotey J, et al. COVID-19 in pregnant women: a systematic review and meta-analysis on the risk and prevalence of pregnancy loss. Hum Reprod Update. 2024. PMID: 38016805. doi:10.1093/humupd/dmad030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。